Inactive Excipients and Other Myths - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Inactive Excipients and Other Myths
Agreement on standards for excipient qualification, development, and fair pricing is underway.

Pharmaceutical Technology
Volume 34, Issue 5, pp. 14

Angie Drakulich
Excipients help a drug to work the right way, but other than that, they provide no active use or function. This statement reflects just one myth industry intends to prove wrong at this month's ExcipientFest Americas conference and exhibition in Puerto Rico. The International Pharmaceutical Excipients Council (IPEC) is collaborating with the conference this year and Pharmaceutical Technology is moderating a unique roundtable at the show on "Leveling the Playing Field for Excipients."

Some of the discussion will focus on excipient qualification and proposed good manufacturing and good distribution standards for developing and using excipients in human drug products (see page s40 of our May supplement for the full story). Another talking point will revolve around novel excipients. Many manufacturers are afraid to develop or use a new excipient because of the related regulatory hurdles, which is leaving many complex drugs that could use a new, better excipient in the lurch. IPEC recently proposed a novel excipient safety evalution procedure (see our November 2009 issue) and is awaiting regulatory and industry feedback.

Finally, the roundtable will address the notion that excipient suppliers who do not apply a risk-based approach to their quality control and supply-chain security programs should not be allowed to sell their excipients at lower cost. In other words, the price should reflect the material's quality and safety (or should it?).

Find out which debates were resolved and which myths were proven wrong in next month's cover story. With excipient suppliers, users, and regulators in the audience, the roundtable is likely to turn into quite a heated debate.

Angie Drakulich is managing editor Pharmaceutical Technology.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here